Sun Pharmaceutical Industries allots ₹7,816 crore non-convertible debentures (NCDs)
Sun Pharmaceutical Industries (BSE: SUNPHARMA) said it has allotted non-convertible debentures (NCDs) of ₹7,816 crore. The company is valued at about ₹4.2 lakh crore.
What happened
Sun Pharmaceutical Industries (BSE: SUNPHARMA) informed the stock exchanges on 26 October 2026 at 12:30 PM that it has allotted non-convertible debentures (NCDs) of ₹7,816 crore.
From the filing: "The base issue size of INR 7,000 crore was fully subscribed and, based on the bids received and accepted, the Company exercised the greenshoe option to the extent of ₹816 crore, out of the greenshoe option of up to INR 3,000 crore."
How big is it?
At ₹7,816 crore, the issue is equal to about 1.9% of the company's market value of ₹4.2 lakh crore.
Company snapshot
Sun Pharmaceutical Industries is a large-cap company in the Healthcare sector, with a market value of about ₹4.2 lakh crore.
The stock last traded at ₹1,750.2, against a 52-week range of ₹1,583.7–₹2,046.9 (14.5% below the high).
Before this filing the shares had moved −6.3% over the month and −11.4% over three months. Average daily turnover over the last 20 sessions was about ₹262 crore.
Promoters held 54.48% at the end of Q1 FY27; 1.65% of promoter shares were pledged. Foreign institutions owned 14.53% and domestic institutions 22.18%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 13,851 | 2,278.6 | 9.5 |
| Q2 FY26 | 14,478 | 3,118 | 13 |
| Q3 FY26 | 15,521 | 3,368.8 | 14 |
| Q4 FY26 | 14,612 | 2,714 | 11.3 |
| Q1 FY27 | 15,300 | 2,894.8 | 12.1 |
What history shows
This is not the company's first fund raising disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Across 30 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +0.9% over five days; 53% of them rose the next day.
Market-wide, 1,642 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- How the money raised is used and, for equity instruments, the dilution for existing shareholders.
- 30 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.